Stephens initiated coverage on ADC Therapeutics with a new price target
$ADCT
Biotechnology: Pharmaceutical Preparations
Health Care
Stephens initiated coverage of ADC Therapeutics with a rating of Overweight and set a new price target of $6.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/8/2024 | $6.00 | Overweight | Stephens |
| 5/30/2024 | Overweight | Cantor Fitzgerald | |
| 3/28/2024 | $11.00 | Buy | Guggenheim |
| 8/10/2023 | Underweight → Neutral | JP Morgan | |
| 4/24/2023 | $7.00 → $2.00 | Neutral → Underperform | BofA Securities |
| 12/6/2022 | $12.00 | Overweight | CapitalOne |
| 11/9/2022 | $14.00 → $7.00 | Buy → Neutral | BofA Securities |
| 9/21/2022 | $5.00 | Overweight | JP Morgan |
LOTIS-5 full enrollment and LOTIS-7 initial efficacy, safety update anticipated by end of 2024 Updated ZYNLONTA® Phase 2 IIT data in indolent lymphomas to be presented at the 66th American Society of Hematology Annual Meeting in December 2024 Discontinuing ADCT-601 program and prioritizing exatecan-based platform for solid tumors Company to host conference call today at 8:30 a.m. EST LAUSANNE, Switzerland, Nov. 7, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the third quarter ended September 30, 2024, and provided recent operational updates.
LAUSANNE, Switzerland, Oct. 31, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, November 7, 2024, at 8:30 a.m. EST to report financial results for the third quarter 2024 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the ev
ZYNLONTA® net sales of $17.0 million in 2Q 2024; Commercial profitability achieved during first half of 2024 LOTIS-7 trial enrollment on track with efficacy and safety data on eligible patients expected by year-end 2024 and mature data on all patients expected in first half of 2025 Full enrollment in LOTIS-5 trial expected before year-end 2024 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the second quarter ended June 30, 2024, and provided operational updates
8-K - ADC Therapeutics SA (0001771910) (Filer)
10-Q - ADC Therapeutics SA (0001771910) (Filer)
8-K - ADC Therapeutics SA (0001771910) (Filer)
Stephens initiated coverage of ADC Therapeutics with a rating of Overweight and set a new price target of $6.00
Cantor Fitzgerald initiated coverage of ADC Therapeutics with a rating of Overweight
Guggenheim initiated coverage of ADC Therapeutics with a rating of Buy and set a new price target of $11.00
LOTIS-5 full enrollment and LOTIS-7 initial efficacy, safety update anticipated by end of 2024 Updated ZYNLONTA® Phase 2 IIT data in indolent lymphomas to be presented at the 66th American Society of Hematology Annual Meeting in December 2024 Discontinuing ADCT-601 program and prioritizing exatecan-based platform for solid tumors Company to host conference call today at 8:30 a.m. EST LAUSANNE, Switzerland, Nov. 7, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the third quarter ended September 30, 2024, and provided recent operational updates.
Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphoma Poster presentation of first interim futility analysis of ongoing investigator-initiated Phase 2 clinical trial studying ZYNLONTA as treatment for r/r marginal zone lymphoma LAUSANNE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced independent, investigator-initiated study abstracts on ZYNLONTA® (loncastuximab tesirine-lpyl) have been accepted for presentation at the 66th American
LAUSANNE, Switzerland, Nov. 4, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two investor conferences in November: Guggenheim Securities Healthcare Innovation Conference Date: November 11, 2024Presentation Time: 11:00 a.m. ETFormat: Fireside ChatSpeaker: Ameet Mallik, Chief Executive Officer Jefferies London Healthcare Conference Date: November 19, 2024Presentation Time: 11:00 a.m. GMTFormat: Fireside ChatSpeaker: Ameet Mallik, Chief Executive
SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)
SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)
SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 20 points on Monday. Shares of Intapp, Inc. (NASDAQ:INTA) fell sharply in today's pre-market trading after Oppenheimer downgraded the stock from Outperform to Perform. Intapp shares tumbled 4.5% to $ 34.67 in the pre-market trading session. Here are some big stocks recording losses in today's pre-market trading session. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) shares dipped 16.2% to $8.79 in pre-market trading. Arcutis Biotherapeutics, last week, reported inducement grants under Nasdaq Listing Rule 5635(c)(4). ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) shares declined 6.4% to $
Cantor Fitzgerald analyst Eric Schmidt initiates coverage on ADC Therapeutics (NYSE:ADCT) with a Overweight rating.
4 - ADC Therapeutics SA (0001771910) (Issuer)
4 - ADC Therapeutics SA (0001771910) (Issuer)
4 - ADC Therapeutics SA (0001771910) (Issuer)
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and AbingworthAdditional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova PartnersFunds will be used to build out Myricx Bio's proprietary N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform and advance its pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigensCompany to establish laboratory operations in London's biotech hub, and expand its management and R&D teamsMichael Bauer from Novo Holdings and Lucille Conroy from Abi
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. "We are pleased to be joining the Russell 2000® Index," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "This is a significant benchmark validating the focused execution of our corporate and capital allocation strategy and our progress toward multiple upcoming expected milestones throughout our hematology and solid tumor portfolios." Th
LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx'), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), today announces the appointment of Dr Chris Martin as independent Chairman to its Board of Directors. Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the ADC space. Dr Martin was instrumental in co-founding ADC Therapeutics (NYSE:ADCT) in Jan 2012 and served as its CEO since inception until May 2022. Under his leadership, ADC Therapeutics grew from a private biotech start-up to a New York
Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-5) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:
Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-4) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:
Submission status for ADC Therapeutics SA's drug ZYNLONTA (ORIG-1) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 04/23/2021. Application Category: BLA, Application Number: 761196, Application Classification:
4 - ADC Therapeutics SA (0001771910) (Issuer)